


## Flosulide

Cat. No.:	HY-U00083
CAS No.:	80937-31-1
Molecular Formula:	C <sub>16</sub> H <sub>13</sub> F <sub>2</sub> NO <sub>4</sub> S
Molecular Weight:	353.34
Target:	COX
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the COA.



### BIOLOGICAL ACTIVITY

Description	Flosulide is a potent and selective COX-2 inhibitor, used for the treatment for inflammatory diseases.
IC <sub>50</sub> & Target	COX-2
In Vitro	Flosulide (1 nM-100 μM) causes a concentration-dependent and finally complete inhibition of PGE <sub>2</sub> production in the OSC-2 cell line, but with no effect on PG formation in the OSC-1 cells. Flosulide completely suppresses mitotic activity of OSC-2 cells, whereas mitotic activity of OSC-1 cells remain unchanged <sup>[2]</sup> .
In Vivo	In normovolemic rats, flosulide increases renal plasma flow (RPF) and glomerular filtration rate (GFR). In hypovolemic rats, flosulide (5-25 mg/kg) reduces RPF and GFR. Flosulide at 5 mg/kg reduces 6-keto-PGF <sub>1α</sub> whereas at 25 mg/kg and after indomethacin at 10 mg/kg a fall in 6-keto-PGF <sub>1α</sub> and TXB <sub>2</sub> appears <sup>[1]</sup> . Flosulide (0.75 mg/day) significantly reduces proteinuria as compared to aspirin treatment. Plasma protein and albumin levels are significantly lower in the aspirin-treated group than in flosulide-treated rats <sup>[3]</sup> .

### PROTOCOL

Cell Assay <sup>[2]</sup>	<p>The proliferation of the esophageal tumor cell lines is determined using the cell proliferation kit II. Tumor cells are incubated with flosulide and NS-398 at different concentrations for 48 h in DMEM containing FCS (10%), penicillin (100 units/mL), and streptomycin (0.1 mg/mL). After this time, the XTT labeling mixture is added, followed by 4 h of incubation and measurement of absorbance at 490 nm.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
---------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### REFERENCES

- [1]. Turull A, et al. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats. *Inflammation*. 2001 Apr;25(2):119-28.
- [2]. Zimmermann KC, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. *Cancer Res*. 1999 Jan 1;59(1):198-204.

---

[3]. Heise G, et al. Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. *Nephron*. 1998 Oct;80(2):220-6.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA